Subchronic and Chronic Toxicity Testing

Subchronic and chronic toxicity tests expose animals to a substance repeatedly over an extended period to detect cumulative, organ-specific, and delayed adverse effects that a single exposure would miss. Subchronic studies typically run for a fraction of the lifespan (commonly around 90 days in rodents), while chronic studies extend over a major part of the lifespan, and both are central to estimating exposure levels below which adverse effects are not observed.

Definition

Subchronic and chronic toxicity testing comprises repeated-dose studies in which a substance is administered over weeks to most of an animal's lifespan to identify target organs of toxicity and to estimate dose-response relationships, including the no-observed-adverse-effect level (NOAEL) used in regulatory assessment.

Scope

The entry covers the rationale for repeated-dose testing, the distinction between subacute, subchronic, and chronic durations, the endpoints examined (clinical signs, clinical chemistry, histopathology), and the derivation of reference points such as the NOAEL and benchmark dose. It is a methodological topic and provides no testing protocols or substance-specific safety thresholds.

Core questions

• Which organs and systems are affected by repeated exposure, and at what doses?
• What is the highest dose at which no adverse effect is observed (the NOAEL)?
• How do effects accumulate or change with increasing exposure duration?
• How are repeated-dose findings used to derive reference values for human exposure?

Key concepts

• Repeated-dose exposure
• Subacute, subchronic, and chronic durations
• No-observed-adverse-effect level (NOAEL)
• Lowest-observed-adverse-effect level (LOAEL)
• Benchmark dose modelling
• Target organ toxicity and histopathology
• Uncertainty (safety) factors

Mechanisms

Repeated-dose studies administer graded doses to groups of animals over a defined period and examine a battery of endpoints: body weight and food consumption, haematology and clinical chemistry, organ weights, and detailed histopathology. By comparing dosed groups with controls, investigators identify the target organs of toxicity and the dose-response relationship. The highest dose without adverse effect (NOAEL) and the lowest dose with an effect (LOAEL) anchor the assessment; increasingly, benchmark dose modelling fits the full dose-response data to estimate a defined level of effect with confidence limits, providing a more statistically grounded reference point. The chosen reference is then divided by uncertainty factors to derive human guidance values.

Clinical relevance

Repeated-dose toxicity data underlie the reference doses, acceptable daily intakes, and safety margins that regulators apply to drugs, food additives, and environmental chemicals. Understanding how these reference points are derived supports critical appraisal of safety evidence. The entry is descriptive of testing methodology and is not a basis for setting individual exposure limits or clinical decisions.

Evidence & guidelines

Repeated-dose testing is standardised through harmonised OECD test guidelines spanning durations from 28-day (subacute) through 90-day (subchronic, e.g. TG 408) to chronic and combined chronic/carcinogenicity studies (e.g. TG 452, TG 453), with parallel guidance for pharmaceuticals under ICH. The derivation of points of departure has been moving from the NOAEL toward benchmark dose approaches, and these guidelines are periodically updated. The National Research Council's 2007 report questioned the long-term reliance on lifetime rodent bioassays and argued for mechanism-based alternatives.

History

Repeated-dose animal bioassays were established through the middle of the twentieth century as the principal means of detecting effects that only emerge with prolonged exposure, and were progressively harmonised through OECD and other test guidelines. The NOAEL became the standard reference point for setting human exposure limits, later supplemented by benchmark dose modelling. The resource-intensive, long-duration nature of chronic studies, especially lifetime carcinogenicity bioassays, has been a major motivation for the development of shorter, mechanism-based alternatives advocated in the National Research Council's 2007 vision.

Debates

Should the NOAEL or the benchmark dose be the standard point of departure?

The NOAEL is limited by depending on the doses actually tested and on study power, whereas benchmark dose modelling uses the whole dose-response curve and yields confidence limits; many bodies now prefer the benchmark dose where data allow, though the NOAEL remains in wide use.

Key figures

• Thomas Hartung

Seminal works

• oecd-tg408-2018
• oecd-tg452-2018
• nrc-2007

Frequently asked questions

What is the difference between subchronic and chronic toxicity testing?

The distinction is duration relative to the animal's lifespan. Subchronic studies expose animals for a fraction of the lifespan (commonly about 90 days in rodents), while chronic studies extend over most of it to detect slowly developing effects.

What is a NOAEL?

The no-observed-adverse-effect level is the highest tested dose at which no statistically or biologically significant adverse effect is detected. It is a reference point derived from a study, not a guaranteed safe exposure level for individuals.